"OncoHealth is a protein biomarker diagnostics company dedicated to revolutionizing screening and diagnostics of cervical cancer and other HPV-associated cancers. Our technology platform includes proprietary biomarkers and robust detection technology that enables the development of easy, high-throughput, and cost competitive assays. This same testing platform can be expanded to other HPV-associated cancers, including anal, oral, head and neck, laryngeal, vulva, penile, and vaginal."

"We believe the current state of the US Health System is sub-par, but doesn't need to be. Despite the world's most renowned doctors and hospitals, and enormous investment (twice as much per individual as any other country in the world), the US ranks 37th in healthcare efficacy according to the World Health Organization. We can do better simply by getting critical information to the right people at the right time and involving patients in their own care. Drawing from experience in other more automated industries, and combining the principles of open standards and open source, we seek to enable providers' access to the data from their legacy systems facilitating new integrated applications and the future of true health information exchange. Our vision is to connect all of the parties in the Health ecosystem safely and securely."

"We're securing the last 2 feet of the Internet: the distance from your computer screen to your eyes. Displays are the most overlooked security vulnerability in the world today. There are technologies to protect data at rest (encryption), and data in motion (VPNs), but until now there has been no software solution to protect valuable information at the point of use - the computer monitor."

"To protect against container tampering, TrakLok has developed an intermodal and international container locking solution and integrated several wireless technologies to track containers globally. Shipments can be tracked through a web accessible information-technology based global tracking system to provide real time visibility of your cargo."

"ARBOVAX, Inc. has a unique technology that modifies arthropod-borne viruses (arboviruses) making them unable to replicate in mammalian cells. Arbovax will leverage this technology through partnerships with pharmaceutical companies to facilitate the development of a portfolio of new and improved human vaccines against the worldwide threat of arthropod-borne diseases."

"Basho Technologies, Inc., founded in January 2008 by a core group of Software Architects, Engineers and Executive Leadership from Akamai Technologies, Inc. (NASDAQ:AKAM) is headquartered in Cambridge, Massachusetts. Basho produces Riak, a distributed datastore that combines high availability, easily-scalable capacity and throughput, and ease of use. Riak's complete availability means that applications built using Riak remain both read- and write-available under almost any operational conditions and without requiring intervention. Available in both an open source and a paid commercial version, Riak provides unprecedented read- and write-availability to web, mobile, and enterprise applications."

"Pique Therapeutics is a biopharmaceutical company seeking to become the leader in the development of new therapeutic vaccines, focused initially on the treatment of cancer.

Pique's lead product is a first-in-class therapeutic vaccine (PT 107) for the treatment of non-small cell lung cancer. PT 107 has completed Phase 1 clinical trials, was well tolerated, and had a very good safety profile in cancer patients. PT 107 showed a dramatic improvement in median overall survival (11 months) for patients with late-stage non-small cell lung cancer, more than doubling the expected 4 to 6 months survival in these patients. Remarkably, over 30% of the patients survived 4 years or longer."

"Protochips, Inc. is an early-stage company developing breakthrough analytical tools that allow more targeted research and development of nano-scale materials. A fundamental problem that exists today is the tools used to observe and the tools used to work with nano-scale materials are separate and independent tools. A strong market need exists to bring these two tools together. Using its own proprietary technology platform, Protochips is addressing this compelling market need by transforming the most widely used tools in nanotechnology - electron and optical microscopes - from cameras into complete nano-scale laboratories. Our products will enable the study of materials for the life and physical sciences in ways currently not possible, and ultimately provide the solution that enables the development and commercialization of revolutionary new nano-scale materials."

"Sensory Analytics, LLC is an emerging leader in advanced coating and film measurement solutions for manufacturers. The Company's innovative lines of SpecMetrix non-contact measurement systems are being actively used by global manufacturers to measure wet and dry coatings on a wide variety of substrates and end-products. Sensory customers are also now using SpecMetrix tools to measure new environmentally preferred coatings within metal packaging, aerospace, industrial and coated film applications."

"Consolidated Asset Recovery Systems (CARS), headquarted in Raleigh, NC, provides a single source, web-based solution for lenders to track, recover, and remarket their non-performing assets. Through a combination of technology and services, CARS is capable of offering lenders a significant reduction in administration costs and losses from bad debt expense."

"STI's mission is to build an effective and profitable technology accelerator for rapid conversion of university scientific breakthroughs into products, services and new technology companies."

"ChaoLogix, Inc. is a semiconductor company with headquarters in Gainesville FL and engineering operations in Melbourne, FL. The company has created, and demonstrated in silicon, an alternative to conventional logic gates, the Chaogate. The chaogate is capable of realizing any logic function, either statically or through dynamic programming. Multiple functions can be realized with fewer gates and therefore with less area relative to competitive approaches."

"At Wilmington Pharmaceuticals, we develop and out-license patient-friendly, fast-dissolving formulations for established medicines. We achieve FDA approval and rapid commercialization for our licensing partners, minimizing regulatory risk while maximizing economic opportunity. Our points of differentiation provide you with an ideal development partner."

Affinergy is developing products to improve clinical outcomes for a broad spectrum of patients while delivering safe and effective products for use by surgeons.